Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AstraZeneca, Hitachi to Jointly Research Pathogenesis and Prognosis of COPD
December 12, 2019
- Teribone Autoinjector Hits Shelves
December 12, 2019
- Eisai Set to Renovate Tsukuba Research Laboratories, Aims for Completion by March 2023
December 12, 2019
- Otsuka Pharmaceutical Names Executive Deputy President Inoue as New Chief
December 12, 2019
- Astellas Charging Ahead with Immuno-Oncology Initiative to Save Non-Responders: Chief
December 11, 2019
- Adcetris Posts Positive Follow-Up Data for 1st-Line Use: Takeda/Seattle Genetics
December 11, 2019
- Maruho Grabs Japan Sales Rights to Peripheral Neuropathy Drug, Near 10% Stake in Solasia
December 11, 2019
- Chugai Expanding Target Range, MOAs in Antibody Drug Discovery with Its Engineering Technologies
December 11, 2019
- 1st Patient Dosed in Japan PII for Daiichi Sankyo’s ATL Drug
December 11, 2019
- Nobelpharma’s Retympa, Senju’s Aibeta Now Available
December 11, 2019
- Healios Poised to Go into the Black with Sakigake-Designated MultiStem, Revs Up Universal Cell Biz
December 10, 2019
- Novo Joins Hands with MSD in Oral Semaglutide Promotion
December 10, 2019
- Pfizer Rolls Out Japan’s 1st Avastin Biosimilar
December 10, 2019
- Takeda Updates Failed Ninlaro Trial Results for Amyloidosis
December 10, 2019
- Ono’s BTK Inhibitor Hits ORR of 88.9% in Types of B Cell Lymphomas: Japan PII
December 10, 2019
- Alzheimer’s Disease Might Be Diagnosed by Blood Sample: Sysmex, Eisai
December 10, 2019
- Kissei’s GnRH Receptor Antagonist Shows Efficacy for Uterine Fibroids in Overseas PIII: Interim Analysis
December 10, 2019
- All-Case PMS Requirement Lifted for Xalkori: Pfizer
December 10, 2019
- Fujifilm Toyama Chemical Completes Construction of New Liposome Formulation Manufacturing Facility
December 10, 2019
- MSD, Taiho to Wind Up Keytruda Copromotion at Year-End
December 9, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…